Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXLJBA)

Drug Name
AP-23588 Drug Info
Synonyms AP-23485; AP-23485 analogs, ARIAD
Indication
Disease Entry ICD 11 Status REF
Osteoporosis FB83.0 Terminated [1]
Cross-matching ID
TTD Drug ID
DMXLJBA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Tyrosine-protein kinase (PTK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Baricitinib DM4ONW5 Rheumatoid arthritis FA20 Approved [3]
Abrocitinib DM8J29L Atopic dermatitis EA80 Approved [4]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [5]
Masitinib DMRSNEU Amyotrophic lateral sclerosis 8B60.0 Phase 3 [6]
KD019 DMEFW3G Brain metastases 2D50 Phase 2 [6]
LEO 124249 DM7W0JE Asthma CA23 Phase 2 [4]
ATI-502 DM8NODR Alopecia ED70 Phase 2 [4]
TD-1473 DMJG7AY Ulcerative colitis DD71 Phase 1 [5]
Aminotriazolopyridine derivative 1 DMW2LZ0 N. A. N. A. Patented [7]
Imidazo[4,5-c]pyridine derivative 2 DMFDRJT N. A. N. A. Patented [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine-protein kinase (PTK) TTJSQEF NOUNIPROTAC Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017871)
2 Foye's Principles of Medicinal Chemistry, Thomas L. Lemke, David A. Williams. 2008. Page(950).
3 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.